Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if treatment with Topotecan by an alternative method, delivering topotecan directly into brain tumors, is safe and well tolerated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03927274
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact
Status Terminated
Phase Early Phase 1
Start date June 20, 2019
Completion date May 24, 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT03796507 - Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation Early Phase 1
Withdrawn NCT04406610 - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients Phase 1/Phase 2
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Active, not recruiting NCT03189420 - Glioma Microenvironment an Exploratory Study
Completed NCT03194906 - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Phase 2
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Completed NCT03779230 - Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse Phase 1/Phase 2
Recruiting NCT03728673 - A Study Utilizing Escitalopram in Glioma Patients Phase 2
Active, not recruiting NCT03496181 - Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
Recruiting NCT03180697 - The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas N/A
Recruiting NCT03949192 - Efficacy of Kangliuwan for Recurrent Grade IV Glioma
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Not yet recruiting NCT03763396 - Azoles Targeting Recurrent High Grade Gliomas Early Phase 1
Terminated NCT03698201 - Blood Biomarker Signature in Glioma
Terminated NCT03436433 - Seizure Prophylaxis in Patients With Glioma or Brain Metastasis Phase 2
Recruiting NCT03750890 - Visual Study of Molecular Genotype in Glioma Evolution
Enrolling by invitation NCT03102112 - Noninvasively Predicting Gene Status of Glioma N/A
Recruiting NCT03935685 - Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ Phase 2
Completed NCT03834740 - A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection Early Phase 1
Recruiting NCT03849430 - Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients